

 	<i>KETOCONAZOLE</i>
<i>Common Technical Document Module 2.7</i>	Clinical Summary Updated, September 2024
	Page 1 of 8

All redactions
under Section 41
and Section 43 of
the Freedom of
Information Act.

KETOCONAZOLE

shampoo 2%

2.7.5 Literature references

[REDACTED]	KETOCONAZOLE
Common Technical Document Module 2.7	Clinical Summary Updated, September 2024
	Page 2 of 8

Literature references

1. Adams, M. L., Meyer, E. R., & Cicero, T. J. (1998). Imidazoles suppress rat testosterone secretion and testicular interstitial fluid formation in vivo. *Biology of reproduction*, 59(2), 248-254.
2. Aggarwal VK, Jain VK, Sangwan S. (2003). Comparative study of ketoconazole versus selenium sulphide shampoo in pityriasis versicolor. *Indian J Dermatol Venereol Leprol*. Mar-Apr;69(2):86-7.
3. Aly R, Berger T. (1996). Common superficial fungal infections in patients with AIDS. *Clin Infect Dis*. 1996 May;22 Suppl 2: S128-32.
4. Ashtiani HA, Rastegar H, Aghaei M, Amirhushang E, Behrooz B, Salout MH (2013). Clinical efficacy of natural formulated shampoo in subjects with dandruff and seborrheic dermatitis. *American Journal of Research Communication: Vol 1(8)* www.usa-journals.com
5. Badri, T., Hammami, H., Bziouche, N., Zouari, B., & Mokhtar, I. (2016). Comparative clinical trial: fluconazole alone or associated with topical ketoconazole in the treatment of pityriasisversicolor. *Tunis Med*, 94(2), 107-111.
6. Bookstaver PB, Watson HJ, Winters SD, Carlson AL, Schulz RM. (2011). Prophylactic Ketoconazole Shampoo for Tinea Capitis in a High-Risk Pediatric Population. *J Pediatr Pharmacol Ther* 2011;16(3):199–203
7. Borda LJ, Wikramanayake TC. (2015). Seborrheic Dermatitis and Dandruff: A Comprehensive Review. *J Clin Investig Dermatol*. Dec;3(2):10.13188/2373-1044.1000019.
8. Borgers M, Van den Bossche H, De Brabander M (1983). The mechanism of action of the new antimycotic ketoconazole. *Am J Med*. Jan 24;74(1B):2-8.
9. Borgers M, Degreef H. (2007). The role of ketoconazole in seborrheic dermatitis. *Cutis*. Oct;80(4):359-63.
10. Buxton PK (1988). Fungal and yeast infections. *British Medical Journal* 296/6619 (420-22).

[REDACTED]	KETOCONAZOLE
Common Technical Document Module 2.7	Clinical Summary Updated, September 2024
	Page 3 of 8

11. Calogiuri, G., Garvey, L. H., Nettis, E., Romita, P., Di Leo, E., Caruso, R., ... & Foti, C. (2019). Skin allergy to azole antifungal agents for systemic use: a review of the literature. *Recent patents on inflammation & allergy drug discovery*, 13(2), 144-157.
12. Carr, M. M., Pryce, D. M., & Ive, F. A. (1987). Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. *British Journal of Dermatology*, 116(2), 213-216.
13. Chatzikokkinou P, Sotiropoulos K, Katoulis A, Luzzati R, Trevisan G. (2008). Seborrheic dermatitis - an early and common skin manifestation in HIV patients. *Acta Dermato venerol. Croat.* 16(4):226-30.
14. Choi, F. D., Juhasz, M. L., & Mesinkovska, N. A. (2019). Topical ketoconazole: a systematic review of current dermatological applications and future developments. *Journal of Dermatological Treatment*.
15. Chowdhry S, Gupta S, D'souza P. (2017). Topical antifungals used for treatment of seborrheic dermatitis. *J Bacteriol Mycol Open Access*. 2017;4(1):1-7.
16. Danby FW, Maddin WS, Margesson LJ, Rosenthal D (1993). A randomized, double-blind, placebo-controlled trial of ketoconazole 20/0 shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. *J Am Acad Dermatol*. Dec;29 (6) : 1008-12.
17. Daneshmend, T. K., & Warnock, D. W. (1988). Clinical pharmacokinetics of ketoconazole. *Clinical pharmacokinetics*, 14, 13-34.
18. Degreef H (1993). New antifungal agents in the treatment of superficial dermatomycoses. *Ann Dermatol Venereol*. 120(1):21-31.
19. Dias, M. F. R. G., Bernardes-Filho, F., Quaresma-Santos, M. V. P., Amorim, A. G. D. F., Schechtman, R. C., & Azulay, D. R. (2013). Treatment of superficial mycoses: review-part II. *Anais brasileiros de dermatologia*, 88, 937-944.
20. Djunaidi, A. M. (2020). Corticosteroid and antifungal alternative treatments for seborrheic dermatitis: a review. *FABAD Journal of Pharmaceutical Sciences*, 45(1), 77-89.
21. Dobrev H and Zissova L (1997). Effect of Ketoconazole 2% Shampoo on Scalp Sebum Level in Patients with Seborrheic Dermatitis. *Acta Derm Venereol (Stoch)* 1997; 77; 132-134

[REDACTED]	KETOCONAZOLE
Common Technical Document Module 2.7	Clinical Summary Updated, September 2024
	Page 4 of 8

22. Elewski, B. E. (2009). Safe and effective treatment of seborrheic dermatitis. *Cutis*, 83(6), 333-8.
23. Fernández-Torres B, Vázquez-Veiga H, Llovo X, Pereiro M Jr, Guarro J. (2000). In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terbinafine of 100 isolates of *Trichophyton rubrum*. *Chemotherapy*. 2000 Nov-Dec;46(6):390-4.
24. Goldenberg Gary, MD. *Optimizing Treatment Approaches in Seborrheic Dermatitis* Mount Sinai School of Medicine, Department of Dermatology, New York, New York. (*J Clin Aesthet Dermatol*. 2013;6(2):44–49)
25. Graybill JR, et al. (1980) Treatment of Coccidioidomycosis with Ketoconazole: Clinical and Laboratory Studies of 18 Patients. *REVIEWS OF INFECTIOUS DISEASES • VOL. 2, NO.4. JULY-AUGUST 1980* © 1980 by The University of Chicago.
26. Green CA, Farr PM, Shuster S (1987). Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. *Br J Dermatol*. Feb;116(2):217-21.
27. Greer DL (2000). Successful treatment of tinea capitis with 2% ketoconazole shampoo. *Int J Dermatol*. Apr;39(4):302-4.
28. Gupta, A. K., Sauder, D. N., & Shear, N. H. (1994b). Antifungal agents: an overview. Part II. *Journal of the American Academy of Dermatology*, 30(6), 911-933.
29. Gupta AK, Batra, Robyn Bluhm, Teun Boekhout, Thomas L Dawson Jr (2004). Skin diseases associated with *Malassezia* species. *J Am Acad Dermatol*. Nov;51(5):785-98.
30. Gupta, A. K., Versteeg, S. G., & Shear, N. H. (2018). Common drug-drug interactions in antifungal treatments for superficial fungal infections. *Expert opinion on drug metabolism & toxicology*, 14(4), 387-398.
31. Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, Saunte DM; Danish Society of Dermatology (2015). Evidence-based Danish guidelines for the treatment of *Malassezia*-related skin diseases. *Acta Derm Venereol*. Jan;95(1):12-9.
32. Herrera-Arellano A, Jiménez-Ferrer E, Vega-Pimentel AM, Martínez-Rivera Mde L, Hernández-Hernández M, et al (2004). Clinical and mycological evaluation of therapeutic effectiveness of *Solanum chrysotrichum* standardized extract on patients with Pityriasis capitis (dandruff). A double blind and randomized clinical trial controlled with ketoconazole. *Planta Med*. Jun;70(6):483-8.

[REDACTED]	KETOCONAZOLE
Common Technical Document Module 2.7	Clinical Summary Updated, September 2024
	Page 5 of 8

33. Kakourou T, Uksal U; European Society for Pediatric Dermatology. (2010). Guidelines for the management of tinea capitis in children. *Pediatr Dermatol.* 2010 May-Jun;27(3):226-8.
34. Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J (2014). Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. *Cochrane Database Syst Rev.* May 19;5:CD009446.
35. Kaul S, Yadav S, Dogra S. (2017). Treatment of dermatophytosis in elderly, children, and pregnant women. *Indian Dermatol Online J;* 8:310-8.
36. Kaur IP, Kakkar S (2010). Topical delivery of antifungal agents. *Expert Opin Drug Deliv.* Nov;7(11):1303-27. Epub 2010 Oct 20.
37. King, C. T., Rogers, P. D., Cleary, J. D., & Chapman, S. W. (1998). Antifungal therapy during pregnancy. *Clinical infectious diseases,* 27(5), 1151-1160.
38. Kyle AA, Dahl MV (2004). Topical therapy for fungal infections. *Am J Clin Dermatol.* 5(6):443-51.
39. Lange DS, Richards HM, Guarnieri J, Humeniuk JM, Savin RC, Reyes BA, et al (1998). Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. *J Am Acad Dermatol.* Dec;39(6):944-50.
40. Manríquez JJ, Uribe P. (2007). Seborrhoeic dermatitis. *BMJ Clin Evid.* Jul 1;2007. pii: 1713.
41. Marais E, Osuch E (2017). Common cutaneous dermatophyte infections of the skin and nails. *South African Family Practice* 2017; 59(3):33-40
42. Marcon MJ, Powell DA (1992). Human Infections Due to *Malassezia* spp. *Clinical Microbiology Reviews,* Apr. 1992, p. 101-119
43. Maretta, M., Maretová, E., & Legáth, J. (2023). The effect of conazoles on reproductive organs structure and function—a review. *Acta Veterinaria Brno,* 92(1), 61-68.
44. Mitu MA, D Lupuliasa, CE Dinu-Pirvu, FS Rădulescu (2011). Ketoconazole in topical pharmaceutical formulations. The influence of the receptor media on the in vitro diffusion kinetics *FARMACIA,* 2011, Vol. 59, 3- revistafarmacia.ro.

[REDACTED]	KETOCONAZOLE
Common Technical Document Module 2.7	Clinical Summary Updated, September 2024
	Page 6 of 8

45. Mokos ZB, Kralj M, Basta-Juzbašić A, Jukić IL (2012). Seborrheic Dermatitis: An Update. *Acta Dermatovenerol Croat*;20(2):98-104
46. Nagpal VB, Jain VK, Aggarwal K (2003). Comparative study of oral and topical ketoconazole therapy in pityriasis versicolor. *Indian J Dermatol Venereol Leprol*. Jul-Aug;69(4):287-8.
47. Odds FC, et al. (1980). The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. *J Antimicrob Chemother*. 1980. PMID: 6244258
48. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. (2015). Topical antifungals for seborrhoeic dermatitis. *Cochrane Database Syst Rev*. 2015 May 2;5:CD008138.
49. Patel, M. A., Aliporewala, V. M., & Patel, D. A. (2021). Common antifungal drugs in pregnancy: risks and precautions. *The Journal of Obstetrics and Gynecology of India*, 71(6), 577-582.
50. Peter RU, Richarz-Barthauer U (1995). Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. *Br J Dermatol*. Mar;132(3):441-5.
51. Piérard-Franchimont C, Arrese JE, Piérard GE (1997) Sebum flow dynamics and antidandruff shampoos. *J. Soc. Cosmet. Chem*.4, 8, 117-121 (March/April)
52. Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. (1998). Ketoconazole shampoo: effect of long-term use in androgenic alopecia. *Dermatology*. 1998;196(4):474-7. doi: 10.1159/000017954.
53. Piérard-Franchimont, C., Goffin, V., Decroix, J., & Piérard, G. E. (2002). A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. *Skin Pharmacology and Physiology*, 15(6), 434-441.
54. Product Monograph Nizoral® (ketoconazole 2% shampoo). Therapeutic Classification Topical Antifungal Agent Date of Revision: March 5, 2019
55. PubChem_Ketoconazole. National Library of Medicine. National Center for Biotechnology Information. Accessed on
56. Rafi AW, Katz RM. (2011). Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. *ISRN Dermatol*. 241953.

[REDACTED]	KETOCONAZOLE
Common Technical Document Module 2.7	Clinical Summary Updated, September 2024
	Page 7 of 8

57. Rajendiran A., Rawat, S., Singh, A., Parveen, A., & Goutham, S. (2021). Role of azole antifungal agents in seborrheic dermatitis & dandruff: a review.
58. Rathi SK (2003). Ketoconazole 2% shampoo in pityriasis versicolor: an open trial. Indian J Dermatol Venereol Leprol. Mar-Apr;69(2):142-3.
59. Saunte DML, Gaitanis G, Hay RJ. (2020). Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment. Front Cell Infect Microbiol. Mar 20; 10:112.
60. Schwartz, R.J., DeAngelis, Y.M. and Dawson, T.L. (2012). Jr. Dandruff and seborrheic dermatitis: a head scratcher. In: Practical Modern Hair Science (T. Evans and R. Wickett, eds), pp. 389–413.
61. Shin JH, Moon HJ, Kang IH, Kim TS, Kim IY, Park IS, et al (2006). Repeated 28-day oral toxicity study of ketoconazole in rats based on the draft protocol for the "Enhanced OECD Test Guideline No. 407" to detect endocrine effects. Arch Toxicol. Dec;80(12):797-803.
62. Shuttleworth D, Squire Ra, Boorman Gc and Goode K. (1998) Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%; Nizoral®) for the control of dandruff/seborrheic dermatitis. Journal of Dermatological Treatment. Volume 9, 1998 - Issue 3 Pages 157-162 | Published online: 12 Jul 2009
63. Sinawe H; Casadesus D. Ketoconazole. (2023). NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Last Update: June 26, 2023
64. Smith, E. B., & Henry, J. C. (1984). Ketoconazole: An Orally Effective Antifungal Agent Mechanism of Action, Pharmacology, Clinical Efficacy and Adverse Effects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 4(4), 199-203.
65. SmPC Nizoral shampoo, 2020; Thornton & Ross Ltd, MAH: Thornton & Ross Ltd. UK, MA No: PL 00240/0451; Date of first authorization/renewal of the authorization: 24/06/200823/10/2020. Date of revision of the text: 23/10/2020
66. Sohn CA (1982). Evaluation of ketoconazole. Clin Pharm. May-Jun;1(3):217-24.
67. Squire RA, Goode K (2002). A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%)

<div style="background-color: black; width: 100%; height: 15px; margin-bottom: 5px;"></div> <div style="background-color: black; width: 100%; height: 15px;"></div>	<i>KETOCONAZOLE</i>
<i>Common Technical Document Module 2.7</i>	Clinical Summary Updated, September 2024
	Page 8 of 8

- and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. *J Dermatolog Treat.* Jun;13(2):51-60.
68. Stefanaki I, Katsambas A. (2010). Therapeutic update on seborrheic dermatitis. *Skin Therapy Lett.* May;15(5):1-4.
69. Straten Vander MR, Hossain MA, Ghannoum MA. (2003). Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. *Infect Dis Clin North Am.* Mar; 17 (1):87-112.
70. Van Cutsem J. The antifungal activity of ketoconazole. *J. Am J Med.* 1983 Jan 24;74(1B):9-15.
71. Van den Bossche H, Willemsens G, Cools W, Cornelissen F, Lauwers WF, van Cutsem JM (1980). In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. *Antimicrob Agents Chemother.* Jun;17(6):922-8.
72. Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. *Pharmacotherapy.* 1984 Nov-Dec;4(6):343-73.